Biotechnology

Viewpoint Molecular Targeting(R) to Present at the H.C. Wainwright BioConnect Conference

January 5, 2022 9:00 AM

CORALVILLE, IA / ACCESSWIRE / January 5, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that Frances L. Johnson MD, Chief Executive Officer and Co-Founder of Viewpoint, will present at the virtual H.C. Wainwright BioConnect Conference taking place January...

Read more

Dermata to Present at the H.C. Wainwright BioConnect Conference

January 5, 2022 8:30 AM

SAN DIEGO, CA / ACCESSWIRE / January 5, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that Gerry Proehl, Dermata's Chairman of the Board, President, and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022....

Read more

Enzolytics, Inc. Announces Production and Sale in North America of “Enzolytics IPF Immune(TM)”, A New Dietary Supplement That Enhances the Immune System

January 4, 2022 7:30 AM

COLLEGE STATION, TX / ACCESSWIRE / January 4, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) announces production and sale in the U.S. and North America of "Enzolytics IPF Immune™," a science-backed liquid nutritional supplement that acts to strengthen the body's immune system. The immune modulator benefits the immune system by fortifying it against infections. The active components in the supplement have been registered with...

Read more

CB Scientific, Inc. to Convene a Special Meeting of Stockholders on Friday, January 14, 2022

January 4, 2022 6:00 AM

Agenda includes transformational matters affecting the Company's position to manage impending growth ESCONDIDO, CA / ACCESSWIRE / January 4, 2022 / CB Scientific, Inc. (OTC PINK: CBSC) ("CBSC" or the "Company") announced today that the company will convene a Special Meeting of Stockholders ("Special Meeting") on Friday, January 14, 2022, at 10:00 a.m. Eastern Standard Time. The meeting venue will be 6887 East Broad Street, Columbus, Ohio 43213,...

Read more

Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402

January 3, 2022 7:00 AM

BOSTON, MA / ACCESSWIRE / January 3, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the successful completion of the sponsor safety review of part 1a of the multi-center, placebo-controlled phase 2a study of dry powder inhaler-formulated...

Read more

Applied UV Announces Closing of $8.0 Million Underwritten Public Offering

December 31, 2021 12:00 PM

MOUNT VERNON, NY / ACCESSWIRE / December 31, 2021 / Applied UV, Inc. (NASDAQ:AUVI)(NASDAQ:AUVIP) ("Applied UV" or the "Company"), an industry leader in air and surface pathogen elimination technology, today announced the closing of its previously announced underwritten public offering of 2,666,667 shares of common stock (the "Common Stock") at a public offering price of $3.00 per share, for aggregate gross proceeds of approximately $8.0 million,...

Read more

M2Bio Rolls Out Sustainable Packaging for Liviana

December 31, 2021 8:30 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / December 31, 2021 /WUHAN GENERAL GROUP, INC. (WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update: M2Bio Sciences is pleased to announce the rollout of its sustainable packaging solution - Hempcelium™ to be piloted and implemented by it's Liviana™ Extra Virgin Olive Oil brand....

Read more

Helix BioPharma Corp. Provides Corporate Update

December 31, 2021 7:30 AM

RICHMOND HILL, ON / ACCESSWIRE / December 31, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to provide a corporate update on initiatives that were undertaken by the Company in 2021. Despite the challenges brought about by the COVID-19 pandemic, 2021 was a productive year for the Company. During the second...

Read more

Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4

December 29, 2021 11:15 AM

• Dosing is expected to begin by April, 2022 KELOWNA, BC / ACCESSWIRE / December 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to report that Independent Review Board ("IRB") approval has been received ahead of schedule for its upcoming DehydraTECH-CBD human hypertension study HYPER-H21-4. This study should "de-risk" outcomes prior to...

Read more

Thermic Science Acquires VIPOnline an International Bank and Crypto/Blockchain Clearing & Trust Company, Establishing Hybrid Traditional Banking with Crypto/Blockchain Options for Account Holders, Including Credit & Debit Cards, Crypto Wallets, Bank Wires, and More

December 29, 2021 9:05 AM

NASHVILLE, TN / ACCESSWIRE / December 29, 2021 / Thermic Science International Corporation, formerly known as Omnicanna Health Solutions, Inc. aka ENDOCAN CORP. (WKN: A1W61J, ISIN: US29271J1097, OTC PINK:ENDO), has acquired an International Hybrid Banking Company, VIPOnline Ltd., UK. https://viponline.uk/ International Bank Account Opening: Business Digital Banking, IBAN/Swift Account Opening Business Virtual/Prepaid Debit/Credit Card Issuing,...

Read more

Enzolytics Reports Its Engagement of Scendea USA, Inc., a Leading International Product Development and Regulatory Consulting Group, To Guide the Progress Toward Clinical Trials and Market Approval for Its Itv-1 Anti-HIV Therapeutic

December 29, 2021 7:30 AM

COLLEGE STATION, TX / ACCESSWIRE / December 29, 2021 / Enzolytics, Inc. has engaged Scendea USA, Inc. (www.scendea.com), a leading international product development and regulatory consulting group, to advance its anti-HIV therapeutic ITV-1 to production, clinical trials and market approval under both the European Medicines Act (EMA) and the U.S. FDA regulatory process. Scendea is a leading product development and regulatory consulting group...

Read more

Applied UV Announces Pricing of $8.0 Million Underwritten Public Offering

December 28, 2021 9:55 PM

MOUNT VERNON, NY / ACCESSWIRE / December 28, 2021 / Applied UV, Inc. (NASDAQ:AUVI)(NASDAQ:AUVIP) ("Applied UV" or the "Company"), an industry leader in air and surface pathogen elimination technology, today announced the pricing of its underwritten public offering of 2,666,667 shares of common stock (the "Common Stock") at a public offering price of $3.00 per share, for aggregate gross proceeds of approximately $8.0 million, prior to deducting...

Read more

Edesa Biotech Reports Fiscal Year 2021 Results

December 28, 2021 4:15 PM

TORONTO, ON / ACCESSWIRE / December 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the fiscal year ended September 30, 2021 and provided an update on its business. During the fiscal year, Edesa reported favorable interim results for both of the company's leading drug candidates, EB05 and EB01. EB05 is being...

Read more

Applied UV Consolidates Supply Chain, Engineering, New Product Development, Logistics and Manufacturing

December 27, 2021 8:00 AM

Consolidation Review Continues to Unlock Further Synergies in Three Recent Acquisitions Max Munn, Founder, President and Director is Appointed Interim CEO MOUNT VERNON, NY / ACCESSWIRE / December 27, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air...

Read more

Applied UV Declares Monthly Preferred Stock Dividend

December 23, 2021 8:00 AM

MOUNT VERNON, NY / ACCESSWIRE / December 23, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of...

Read more

American CryoStem Announces Completion of Patient Recruitment for its Post-Concussion Syndrome (PCS) ATCELL(TM) Phase I Clinical Trial

December 22, 2021 1:00 AM

EATONTOWN, NJ / ACCESSWIRE / December 22, 2021 / American CryoStem Corporation (OTC PINK:CRYO) a clinical-stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and therapies announced today that its clinical study team has completed recruiting subjects for its Investigational New Drug (IND) Phase I Clinical Trial for Post-concussion syndrome. The singe site, multi-dosage blinded study is being conducted by...

Read more

Apollo Endosurgery Announces New $100 Million Senior Secured Term Loan Facility from Innovatus Capital Partners, LLC

December 21, 2021 4:50 PM

$35 million funded at close to refinance existing debt, extend maturity and lower interest expense Additional borrowing capacity provides minimally dilutive growth capital and strategic flexibility AUSTIN, TX / ACCESSWIRE / December 21, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it has entered into a debt financing...

Read more

RepliCel Terminates License Agreement with Shiseido

December 21, 2021 11:10 AM

VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today that the dispute between Shiseido and RepliCel has led to the Company electing to terminate the license agreement with Shiseido. The Company's decision is a legal step in its pursuit of a resolution of its...

Read more

Viewpoint Molecular Targeting(R) Presents Preclinical Data from VMT-𝛼-NET, Theranostic in Development for the Treatment and Diagnosis of Neuroendocrine Tumors, at the Pacifichem 2021 Congress

December 21, 2021 9:00 AM

Optimized 203Pb/212Pb image-guided alpha-particle radionuclide therapy for SST2R expressing tumors Preclinical data of VMT-𝛼-NET demonstrated to significantly improve cell binding, tumor accumulation/retention and renal clearance of an SSTN analog VMT-𝛼-NET currently in a Phase 1 imaging study to be followed by Phase 1/2a therapy study for the treatment of neuroendocrine tumors (NETs) being conducted at the University of Iowa CORALVILLE, IA /...

Read more

BioInvent Moves to NASDAQ Stockholm’s Mid Cap Segment

December 20, 2021 3:20 AM

LUND, SWEDEN / ACCESSWIRE / December 20, 2021 / BioInvent International (STO:BINV) Lund, Sweden - December 20, 2021 - BioInvent International AB ("BioInvent") (NASDAQ Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the company will be moved to the Mid Cap segment on Nasdaq Stockholm from January 3, 2022. The change...

Read more